Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients

Iodine therapy is the best treatment for graves disease.Most patients receive methimozale prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.

Some physicians advice to discontinue methimazole 3 days before radioiodine therapy and others prefer longer off - methimazole period which bothers most patients. This study aimed to evaluate optimum time for methimazole discontinuation in graves disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Graves Disease Autoimmune Diseases Endocrine System Diseases Exophthalmos Eye Diseases Goiter Hyperthyroidism Immune System Diseases Orbital Diseases Thyroid Diseases

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Mashad University of Medical Sciences

Mashhad, Razavi Khorasan Province, 91766, Iran

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

age 18-65
graves disease(TSH<0.1 &increased FT4 & positive TSI
one or more bartlena criteria for radio-iodine therapy
24 hour RAIU>25%
euthyroidism after methimazole treatment

Exclusion criteria

pregnancy or lactation
moderate or severe graves ophthalmopathy
CHF or coronary heart disease
palpable thyroid nodule
lithium or amiodarone or lugol or ipodate treatment
recent imaging with contrast agent
very large goiter(more than 150 gram)

Treatment and study plan

methimazole

Drug

Methimazole was stopped 24-48 before radio-iodine therapy

Primary outcomes

thyroid function tests over one year after radioiodine therapy

Time frame: months 1 , 3 ,6,9,12

thyroid function test may change over one year . In order to consider the patients as cured ,thyroid function tests should reveal hypothyroidism or euthyroidism . In order to rule out temporary hypothyroidism the tests should be repeated after 6 months of radioiodine therapy.

Sponsors and collaborators

Lead sponsor

Mashhad University of Medical Sciences

Other

Registry information

Important dates

Study start: 2010
Primary completion: 2012
Study completion: 2012
First posted: Mar 22, 2012
Registry last updated: Mar 22, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed